Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment

Jun Ku Chung[a,b], Eric Plitman[a,b], Shinichiro Nakajima[b,c,d,e], Tiffany W. Chow[a,c,e],
M. Mallar Chakravarty[f,g], Fernando Caravaggio[a,b], Philip Gerretsen[b,c,e], Eric E. Brown[b,c],
Yusuke Iwata[b,d], Benoit H. Mulsant[c], Ariel Graff-Guerrero[a,b,c,d,e,*] and for the Alzheimer's Disease
Neuroimaging Initiative[†]

[a] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
[b] Multimodal Imaging Group – Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada
[c] Department of Psychiatry, University of Toronto, Toronto, Canada
[d] Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan
[e] Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada
[f] Cerebral Imaging Centre, Douglas Mental Health Institute, McGill University, Montreal, Quebec, Canada
[g] Department of Psychiatry and Biomedical Engineering, McGill University, Montreal, Quebec, Canada

Abstract. Mounting evidence associates a lifetime history of major depression (LMD) with an increased risk for Alzheimer's disease (AD). Studies have shown that major depression (MD) is strongly linked to pathophysiological markers of AD, such as cortical amyloid-β (Aβ) burden. However, no imaging studies have shown *in vivo* whether an LMD is linked to increased Aβ accumulation in patients with mild cognitive impairment (MCI) in four cortical regions that have been highly associated with increased Aβ deposition in previous literature: frontal, cingulate, parietal, and temporal. Drawing from the ADNI database, we found that patients with amnestic MCI (aMCI) and an LMD ($n = 39$) had significantly higher ^{18}F-Florbetapir standardized uptake value ratios, a surrogate measure of Aβ deposition, mainly in the bilateral frontal cortex, compared to patients with aMCI without an LMD ($n = 39$) ($p = 0.02$). This difference was not explained by current depressive symptoms, vascular risk factors, or the use of different PET scanners. The results were reliable employing two independent methods for analysis: region-of-interest and voxel-based analyses. Increased Aβ in the bilateral frontal lobes may be a biomarker of depressive symptomology in aMCI patients. Further studies should test whether higher Aβ predicts future conversion into AD in this population.

Keywords: Alzheimer's disease, amyloid-β, major depression, mild cognitive impairment, positron emission tomography

INTRODUCTION

Several studies link a lifetime history of major depression (LMD) with an increased risk of developing late-onset Alzheimer's disease (AD) [1–4]. Two meta-analyses report that major depression (MD) can almost double the risk of developing dementia [5, 6]. Moreover, a single episode of late-life depression is found to elevate the risk of AD by 4- to 6-fold [7]. Reynolds et al. reported that MCI patients with late-life depression who were on donepezil, which is a treatment for AD, showed decreased conversion rate to dementia, in comparison to those who were on placebo [8].

*Correspondence to: Ariel Graff-Guerrero, MD, PhD, Multimodal Imaging Group – Research Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada. Tel.: +1 416 535 8501/Ext. 4834; E-mail: ariel.graff@camh.ca.

Depression is a potentially modifiable risk factor for AD and projections indicate that successful interventions targeting late-life depression might reduce the prevalence of AD by up to 10.6% globally [9].

Mild cognitive impairment (MCI) is thought to be a transitional risk state between normal aging and AD [10]. The conversion rate from MCI to AD varies from as low as 10% to as high as 100%, depending on the follow-up period and controversially, the amnestic, as opposed to the non-amnestic type of MCI [11–13]. Additionally, among patients with MCI, depression is one of the most prevalent neuropsychiatric symptoms with a prevalence rate of up to 20% [14]. Patients with MCI and depressive symptoms are more likely to convert to AD than those without depression [15, 16]. This is supported by an autopsy study, which reported that patients with AD and MD had more hippocampal plaques and neurofibrillary tangles than AD patients without MD [17]. This result suggests that depression adds to the amyloid burden above and beyond the AD itself.

Through the use of positron emission tomography (PET) radiotracers, such as ^{18}F-2-(1-[16]-ethylidene) malononitrile (FDDNP), ^{11}C-Pittsburgh Compound B (PIB), and ^{18}F-Florbetapir (AV-45), it is possible to estimate amyloid-β (Aβ) deposition *in vivo* [18, 19]. A recent study using AV-45 revealed that Aβ accumulation is increased in frontal, temporal, and parietal regions of depressed patients, in comparison to non-depressed patients [20]. Another study reported that current depression scores in patients with MCI are associated with increased lateral temporal FDDNP binding [21]. In addition to frontal, parietal, and temporal regions, the cingulate region has been linked to increased Aβ accumulation [22]. Taken together, current evidence supports the notion that the cortical Aβ burden may be higher in depressed MCI patients within frontal, cingulate, parietal, and temporal regions.

However, to date, no previous PET study has directly tested whether an LMD is linked to Aβ accumulation in these aforementioned regions. Using data from Alzheimer's Disease Neuroimaging Initiative (ADNI) databases [23], we compared the AV-45 standardized uptake value ratio (SUVR) in these four region of interests (ROIs) between amnestic MCI patients with an LMD (aMCI+LMD) and amnestic MCI patients without an LMD (aMCI-LMD). Investigating these *a priori* regions, we hypothesized that the aMCI+LMD group would have higher AV-45 SUVR in frontal, cingulate, parietal, and temporal region in comparison to the aMCI-LMD group.

MATERIALS AND METHODS

Study patients and diagnosis

The entire dataset was downloaded from ADNI-1, ADNI-2, and ADNI Grand Opportunity (ADNI-GO) databases on 29 March 2014 [23]. The ROI-based AV-45 dataset that we used was updated as of 2 May 2014. Briefly, in ADNI-1, 800 participants, including controls, patients with aMCI, and patients with mild AD, were recruited from 50 different sites in Canada and the United States [24]. Each subject was either an English or Spanish speaker, aged between 55 and 90 years, and had a study partner able to provide an independent evaluation of functioning. The key eligibility criteria for aMCI participants were: a Mini–Mental State Examination (MMSE) score [25] of equal or higher than 24 of 30, a memory complaint, having objective memory loss measured by education adjusted scores on the Wechsler Memory Scale [26] Logical Memory II, a Clinical Dementia Rating (CDR) score [27] of 0.5, an absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living and an absence of dementia. In ADNI-2, 100 early-stage aMCI patients and 150 late-stage aMCI patients were recruited from 55 different sites from Canada and the United States [28]. In ADNI-GO, 200 participants, including patients with mild AD and early aMCI were recruited. Eligibility criteria in ADNI-2 and ADNI-GO were identical to those in ADNI [29]. Scores on the Functional activities questionnaire (FAQ) [30], Geriatric Depression Scale (GDS) [31] and Neuropsychiatric Inventory (NPI) [32], Modified Hachinski Ischemic scores [33], which assesses vascular dementia, history of cardiovascular disease (CVD), systolic blood pressure and current smoking status, were obtained from ADNI-1, ADNI-2, and ADNI-GO. For our current study, we only included patients with aMCI who had both a T1-weighted magnetic resonance imaging (MRI) scan and a AV-45 PET scan completed within a 6-month interval between each scan (68 patients completed within a month interval between each scan, 5 patients within a 2-month interval, 3 patients within a 3-month interval and 2 patients within a 6-month interval).

aMCI-LMD patients were matched to aMCI+LMD patients based on following conditions. Discrete factors such as gender, apolipoprotein E4 (apoE4) genotype, race, ethnicity, and marital status were matched between the two groups; continuous factors, including age, education years, and scores on MMSE, FAQ, and CDR were also matched. The exclusion

criteria included missing covariates, missing information about PET scans, ambiguous descriptions about depression, temporal gap between medical assessments and the scans. As a result, this study included 39 aMCI+LMD patients and 39 matched aMCI-LMD patients.

Lifetime history of major depression

The presence of an LMD was determined using patients' medical history from ADNI-1, ADNI-GO, and ADNI-2. Medical history was obtained by trained research assistants from aMCI patients, their caretakers or informants during ADNI screening and follow-up visits [34]. Using the keyword "depress†" in the medical history database, LMD was defined as having at least one major depressive episode prior to the PET scan. Patients who were actively depressed were also included. For this study, the definition of major depression excluded the following types of depression: mild depression, postpartum depression, situational or reactive depression, bipolar/depression type, and depression/anxiety type, as recorded in the ADNI medical history.

Cortical Aβ deposition

Data for AV-45 imaging were available from ADNI-2 and ADNI-GO. AV-45 data were acquired from PET scanners located at 59 different acquisition sites. The detailed information about the technical scan procedure is described online [35]. Each of the two ADNI initiatives reported ROI-based AV-45 SUVR. ROIs included bilateral frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal cortices. ROI-based AV-45 SUVR was calculated by dividing the AV-45 mean from one of the ROIs into the AV-45 mean of a composite reference region (average of whole cerebellum, brainstems/pons, and eroded subcortical white matter). More details about the PET analysis are described online [36].

Scanning and imaging procedure

AV-45 was prepared by ADNI study coordinators, after referencing Avid Radiopharmaceuticals, Inc. Clinical Supplies Guidance Document for the necessary steps prior to radiotracer injection [37, 38]. With participants' informed consent, a 370 MBq (10 mCi ± 10%) bolus injection of AV-45 was administered. A continuous 20-min PET scan occurred 50-min post-injection and was reconstructed

in 4 frames of 5-min each. Scans were acquired from different PET scanners depending on the site ($n = 13$): Siemens/CTI, Model = HR+ ($n = 19$); Philips Medical Systems, Model = GEMINI TF series ($n = 14$); GE Medical System, Model = Discovery ST series ($n = 13$); CPS, Model = LSO PET/CT HI-REZ ($n = 2$); SIEMENS, Model = 1094 ($n = 6$); GE MEDICAL SYSTEMS, Model = Discovery LS series ($n = 8$); Philips Medical Systems, Model = Guardian Body(C) ($n = 4$); Philips Medical Systems, Model = Allegro Body(C) ($n = 3$); GEMS, Model = Advance ($n = 3$); SIEMENS, Model = Biograph64 ($n = 2$); Siemens/CTI, Model = ACCEL ($n = 2$); GE MEDICAL SYSTEMS, Model = Discovery 600 ($n = 1$); and SIEMENS, Model = SOMATOM Definition AS_mCT ($n = 1$). Each subject also had an MRI scan session, including a T1-weighted scan, which was employed for spatial normalization during voxel-based analysis. All patients' PET-AV-45 scans and last clinical assessment of their diagnostic status were completed approximately at the same time.

Positron emission tomography analysis

PET analysis was performed using Analyze 6.0 software and Statistical Parametric Mapping 2.0 (SPM2, http://www.fil.ion.ucl.ac.uk/spm/) running on Matlab 6.5. Using Analyze 6.0 software, an average PET scan was constructed using the four frames of PET-AV-45 scans for each subject. Consequently, each subject's T1-weighted MRI scan was coregistered to average PET images into native PET space. Next, the coregistered T1-weighted MRI scan and the average PET scan were normalized into Montreal Neurological Institute (MNI) space using the T1-weighted MRI template provided by SPM2 as the target. The MNI normalized average PET images of the radiotracer uptake were converted to SUVR images. The SUVR images were generated by dividing the average PET image into the mean radioactivity extracted from the cerebellar gray matter. The cerebellar grey matter radioactivity was defined using the Automated Anatomical Labeling template [39], avoiding cerebellar white matter. SUVR images were smoothed with a Gaussian filter in each coordinate direction with a kernel of 8-mm for the voxel-based analysis. The ROI analysis was performed using region-specific SUVRs from frontal, anterior/posterior cingulate, lateral parietal and lateral temporal cortices, as reported by the ADNI database (updated on 2 May 2014).

Statistical analysis

The demographic and clinical characteristics between aMCI+LMD and aMCI-LMD groups were compared by independent *t*-tests.

The ROI analysis was performed using univariate analyses of covariance (ANCOVA) to investigate whether differences existed in region-specific AV-45 SUVR between the two groups, controlling for potential confounds such as: GDS score at time of scanning; Modified Hachinski Ischemic score at the screening visit; current smoking status; NPI total score at time of scanning; medical history of CVD; apoE4 genotype; FAQ score at the time of scanning; systolic blood pressure at the time of scanning, and PET scanner models. Medical assessments and PET scans occurred within a maximum of a year interval between each other. Any participants with missing information regarding these covariates were excluded from the study (Fig. 1). The statistical tests were performed using Statistical Package for the Social Sciences Version 21.0 (IBM, New York, US). Based on our *a priori* hypotheses, the statistical significance was assumed at $p < 0.05$.

Fig. 1. Flow chart showing the selection of aMCI patients with a lifetime history of depression and aMCI patients without a lifetime history of depression from ADNI database. aMCI, amnestic mild cognitive impairment; aMCI+LMD, aMCI with a lifetime history of major depression; aMCI-LMD, aMCI without a lifetime history of major depression; AV-45, ^{18}F-Florbetapir; MRI, magnetic resonance imaging; PET, positron emission tomography.

Voxel-based PET analysis

Voxel-based analysis was performed using SPM2. A general linear model analysis for two-independent samples was performed to compare AV-45 SUVR images between aMCI+LMD and aMCI-LMD groups used in the ROI analysis. We reported areas only if they met the joint criteria of *p*-uncorrected <0.01 and an arbitrary cluster size of more than 12 voxels (~3.75 the isotropic kernel used for smoothing with a voxel size of 2 mm) in the *a priori* regions defined in the ADNI study: frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal cortices. No *a priori* regions were considered significant if p-FDR corrected <0.05.

RESULTS

Demographic and clinical profile

Matching variables were similar in aMCI+LMD and aMCI-LMD groups including age, education years, MMSE score, CDR score, gender, apoE4 genotype, race, ethnicity, and marital status. Confounding factors, such as current GDS score, modified Hachinski Ischemic score, current smoking status, NPI total score, medical history of CVD, FAQ score, and systolic blood pressure were similar between groups (Table 1).

Comparison of AV-45 SUVR between aMCI-LMD and aMCI+LMD

Figures 2 and 3 show that the aMCI+LMD group had higher frontal AV-45 SUVR than the aMCI-LMD group. The univariate ANCOVA (Table 2), controlling for current GDS score, modified Hachinski ischemic scale score, current smoking status, medical history of CVD, apoE4 genotype, FAQ score, systolic blood pressure, and the different PET scanners, showed that the aMCI+LMD group had higher frontal AV-45 SUVR than the aMCI-LMD group (F (76) = 5.62 p = 0.02). The univariate ANCOVA for the cingulate, parietal and temporal regions showed that there were no differences in AV-45 SUVR within these areas (F (76) = 0.14,

Table 1

Comparison of demographic and clinical variables between aMCI patients with a lifetime history of major depression and aMCI patients without a lifetime history of major depression

Demographic variables	aMCI-LMD (n = 39)		aMCI+LMD (n = 39)		p-value
	mean	SD	mean	SD	
Age, years	71.39	6.86	68.90	6.86	0.11
Education years	16.38	2.74	15.79	2.85	0.35
MMSE score	27.10	4.05	27.92	1.58	0.24
CDR score	2.01	2.58	2.00	1.18	0.98
Modified Hachinski	0.51	0.56	0.49	0.64	0.68
GDS score	1.72	1.36	2.51	2.27	0.07
Systolic blood pressure	133.72	16.28	128.18	16.35	0.14
NPI total score	3.09	4.02	5.57	9.16	0.20
FAQ	3.38	5.04	4.05	4.80	0.55
Demographic variables	Number (frequency [%])		Number (frequency [%])		p-value (two-tailed)
CVD+	24 (61.54)		23 (58.97)		1.00
Smoking+	2 (5.13)		3 (7.69)		1.00
White	37 (94.87)		39 (100.00)		0.24
Hispanic/Latino	2 (5.13)		1 (2.56)		1.00
Married	33 (84.62)		33 (84.62)		1.00
Females	18(46.15)		22(56.41)		0.50
0 ApoE4	19 (48.72)		20 (51.28)		0.86
1 ApoE4	17 (43.59)		15 (38.46)		0.86
2 ApoE4	3 (7.69)		4 (10.26)		0.86

aMCI-LMD and aMCI+LMD groups were matched in all the demographic variables listed above (*t*-test, two-tailed for the continuous demographic variables; χ^2-test, two-tailed for the discrete demographic variables). aMCI, amnestic mild cognitive impairment; aMCI+LMD, aMCI with a lifetime history of major depression; aMCI-LMD, aMCI without any lifetime history of major depression; ApoE4, apolipoprotein E4; 0 ApoE4, number of 0 ApoE4 allele holders; 1 ApoE4, number of 1 ApoE4 allele holders; 2 ApoE4, number of 2 ApoE4 alleles holders; CDR, the Clinical Dementia Rating; CVD+, presence of history of cardiovascular disease; FAQ, the Functional Activities Questionnaire score; GDS, the Geriatric Depression Scale score; MMSE, the Mini-Mental state examination score; Modified Hachinski, the Modified Hachinski Ischemic scale score; NPI, the Neuropsychiatric Inventory total score; Smoking+, currently smoking; χ^2-test, Chi-squared test/Fischer's Exact test.

Fig. 2. Scatterplots representing the AV-45 SUVR between aMCI patients with a lifetime history of major depression and aMCI patients without a lifetime history of major depression. a) Mean frontal AV-45 SUVR; b) Mean Cingulate AV-45 SUVR; c) Mean parietal AV-45 SUVR; d) Mean temporal AV-45 SUVR. The LMD+ group showed significantly higher AV-45 SUVR in the frontal region than the LMD+ group. There is no significant difference in other regions between two groups. *indicates statistical significance at $p < 0.05$, two-tailed. Error bars represent SD. aMCI, amnestic mild cognitive impairment; AV-45 SUVR, ^{18}F-Florbetapir standardized uptake value ratio; LMD-, aMCI patients without a lifetime history of major depression; LMD+, aMCI patients with a lifetime history of major depression.

$p = 0.71$; F $(76) = 0.45$, $p = 0.50$ and F $(76) = 0.76$, $p = 0.39$, respectively). There was no difference in global AV-45 SUVR, which is the average AV-45 SUVR of the frontal, anterior cingulate, precuneus, and parietal cortex AV-45 SUVR uptake relative to the cerebellum reference region, between two groups (F $(76) = -1.02$; $p = 0.31$).

Voxel-based analysis

The brain areas with higher SUVR in the aMCI+LMD group, in comparison to the aMCI-LMD group, are described in Table 3 and illustrated in Fig. 3. The brain areas with higher SUVR in the aMCI+LMD group, in comparison to the aMCI-LMD group, are described in Table 3 and illustrated in Fig. 3. The regions include: right medial frontal gyrus, right middle frontal gyrus, left superior frontal gyrus, left inferior frontal gyrus, right superior temporal gyrus,

and left anterior cingulate (Cohen's effect size = 0.72, 0.64, 0.65, 0.60, 0.66, and 0.65, respectively).

DISCUSSION

Our study showed higher AV-45 SUVR in the frontal cortex (Cohen's effect size = 0.53) of the aMCI+LMD group, in comparison to the aMCI-LMD group. The increased AV-45 SUVR was found employing a pre-defined set of ROIs informed directly by the ADNI database and confirmed by a voxel-based parametric analysis. The confirmatory voxel-based analysis found that the increased AV-45 SUVR was in the bilateral frontal cortex including the left dorsolateral prefrontal cortex (DLPFC), bilateral orbitofrontal cortex (OFC), and medial prefrontal cortex (mPFC). In addition, the voxel-based analysis reported increased AV-45 SUVR in the superior temporal gyrus and anterior cingulate. The ROI global AV-45 SUVR was no different

Fig. 3. Cortical render comparing AV-45 SUVR between aMCI patients with a lifetime history of major depression and aMCI patients without a lifetime history of major depression. The regions that show higher AV-45 SUVR in aMCI+LMD mainly include bilateral prefrontal cortex. Few regions in the right temporal region also show higher AV-45 SUVR in aMCI+LMD group. aMCI+LMD, patients with amnestic mild cognitive impairment with a lifetime history of major depression; AV-45 SUVR, ^{18}F-Florbetapir Standardized uptake value ratio.

between the two groups. This is consistent with previous findings that reported no difference in global Aβ deposition between depressed and non-depressed persons [20, 40].

Participants were matched on potential confounding factors, such as age, gender, education years, race, ethnicity, CDR score, FAQ score, MMSE score, NPI score, apoE4 genotype, and marital status. Additional analyses were also conducted, controlling for current GDS score, vascular risk factors, and different PET scanners, to ensure that any difference in AV-45 SUVR was related to an LMD, rather than any other variables. Moreover, according to the vascular depression hypothesis, the central mechanism of depression is disruption of the prefrontal system through accumulation of frontal vascular lesions [41]. As there is high comorbidity among depression, vascular risk factors, and vascular disease, we controlled or matched for vascular risk factors that may contribute to the association between Aβ accumulation and depressive symptoms [42]. This approach reduced the possibility that vascular damage may lead the higher Aβ accumulation in frontal regions showed in the aMCI+LMD group. Additionally, we also observed statistically significant increase of AV-45 SUVR in the frontal region of the aMCI+LMD group without controlling for these covariates (Fig. 2).

Our study identified increased AV-45 in the bilateral frontal cortex of the aMCI+LMD group. The potential mechanisms by which an LMD can elevate the level of Aβ deposition in the frontal region of aMCI patients are currently unclear. Nonetheless, cortisol has been implicated in the pathology of depression and Aβ deposition [43, 44]. Stress-level glucocorticoid administration increases Aβ formation by elevating the levels of amyloid-β precursor protein (AβPP) and AβPP cleaving enzyme, suggesting that cortisol may facilitate the formation of Aβ plaques [45]. According to the glucocorticoid cascade hypothesis of depression, stress elevates glucocorticoid levels, which can in turn have neurotoxic effects in the hippocampus.

Furthermore, neuroinflammation has also been associated with the pathology of depression and Aβ deposition [46]. There is evidence showing that chronic neuroinflammation may explain the structural changes, including the formation of Aβ plaques, in dementia and other types of neurodegenerative disorders [47]. Pro-inflammatory cytokines are thought to regulate a cascade, which ultimately results in over-secretion of cortisol [48]. There are studies suggesting that Aβ deposition in humans occurs early in the prefrontal region [49, 50]. Difference in cortisol response may mechanistically explain the link between an LMD and increased Aβ accumulation in the frontal lobes [51]. Thus, cortisol and neuroinflammation may contribute to the elevation of Aβ deposition levels in the aMCI+LMD group. Further research is needed to elucidate the mechanistic explanation for increased Aβ deposition in this population.

Another explanation that links depression and Aβ deposition is modulation at the level of the N-methyl-D-asparate receptor (NMDAR) [52]. Dysregulation of calcium influx through the NMDAR can increase the level of Aβ by increasing the expression of amyloidogenic isoforms of AβPP [52]. A recent review notes that depression may induce chronic stimulation of the NMDAR, ultimately resulting in elevated levels of Aβ due to increased calcium influx [53]. Thus, cortisol, neuroinflammation, and chronic stimulation of the NMDAR may explain the pathway linking MD and elevated Aβ deposition.

It is widely accepted that frontal dysfunction is implicated in the pathophysiology of depression [54]. Meta-analyses report that MD may be linked to dysfunction of frontal connectivity to other cortical and subcortical regions [55, 56]. Moreover, brain-imaging studies have reported that depressed patients show

Table 2
Comparison of region-of-interest based AV-45 SUVR between aMCI patients with a lifetime history of major depression and aMCI patients without a lifetime history of major depression

Regions of Interest	aMCI-LMD ($n = 39$) SUVR		aMCI+LMD ($n = 39$) SUVR		F-value	p-value
	mean	(SD)	mean	(SD)		
Frontal*	1.33	0.24	1.47	0.29	5.62	0.02*
Cingulate	1.40	0.24	1.39	0.26	0.14	0.71
Parietal	1.33	0.24	1.31	0.24	0.45	0.50
Temporal	1.26	0.22	1.23	0.24	0.76	0.39

The univariate ANCOVA analysis showed that patients with a lifetime history of major depression have significantly higher AV-45 SUVR in the frontal region, but not in other regions, after controlling for the covariates, including current GDS score, current smoking status, modified Hachinski ischemic scale score, FAQ score, apoE4 genotype, systolic blood pressure, medical history of CVD, and the different PET scanners. *indicates statistical significance at $p < 0.05$, two-tailed. aMCI, amnestic mild cognitive impairment; aMCI+LMD, aMCI with a lifetime history of major depression; aMCI-LMD, aMCI without any lifetime history of major depression; ANCOVA, analysis of covariance; AV-45 SUVR, ^{18}F-Florbetapir standardized uptake value ratio.

Table 3
Talaraich coordinates of *a priori* regions that show higher AV-45 SUVR in aMCI patients with a lifetime history of major depression in comparison to aMCI patients without a lifetime history of major depression

Coordinate mm			Regions	Hemisphere	BA	Cluster size	Values	
x	y	z					T	p
4	66	14	Medial frontal gyrus	Right	10	287	3.16	0.003
24	64	6	Middle frontal gyrus	Right	10		2.81	0.003
30	60	10	Middle frontal gyrus	Right	10		2.58	0.006
−20	68	2	Superior frontal gyrus	Left	10	73	2.82	0.003
−30	62	4	Superior frontal gyrus	Left	10		2.43	0.009
−50	38	12	Inferior frontal gyrus	Left	46	15	2.63	0.005
8	−8	52	Medial frontal gyrus	Right	6	28	2.75	0.004
38	14	−32	Superior temporal gyrus	Right	38	63	2.86	0.003
0	30	−2	Anterior cingulate	Left	24	43	2.85	0.003

This table highlights the regions of higher AV-45 SUVR in the aMCI patients with a lifetime history of major depression, in comparison to aMCI patients without a lifetime history of major depression. They were included if they were statistically significant at $p < 0.01$, uncorrected. aMCI, amnestic mild cognitive impairment; AV-45 SUVR, ^{18}F-Florbetapir Standardized uptake value ratio; BA, Brodmann area.

decreased activity in frontal regions during functional imaging tasks [57]. We observed that the aMCI+LMD group had higher AV-45 in the DLPFC than the aMCI-LMD group. The DLPFC is thought to suppress negative affect through top-down inhibition of the amygdala [58], which may be a protective mechanism against depression [59]. A study examining Vietnam veterans showed that DLPFC lesions were positively correlated with current depression scores [60]. Another study reported that DLPFC cerebral blood flow predicts the severity of depressive symptoms in MD patients [61]. DLPFC lesions are also associated with labile affects, poor goal-directed activity, and depression [62–64]. Furthermore, a recent study revealed that the number of depressive episodes, but not the current depressive state, was associated with cortical thinning in the left prefrontal cortex [65]. Therefore, our findings that the aMCI+LMD group had increased Aβ accumulation in the PFC, compared to the aMCI-LMD group, are in keeping with a frontal dysfunction model of depression.

While there is evidence that left frontal lesions are associated with depression [66, 67], the right frontal region has been also implicated in depression [68]. A study suggested a strong link between late-life onset depression and right frontal atrophy, but not with left frontal atrophy [69]. Neurostimulation studies further support the evidence of frontal involvement in MD. Left PFC repetitive transcranial magnetic stimulation (r-TMS) or transcranial direct current stimulation (tDCS), is effective for the treatment of depression [70]. Both high-frequency r-TMS and anodal tDCS to the left PFC resulted in significantly higher antidepressant efficacy compared to sham stimulation [71, 72]. On the other hand, low-frequency r-TMS, which elicits inhibitory action, targeting the right DLPFC, but not the left DLPFC, was shown to be effective in MD patients [73]. Together, these findings suggest that abnormalities in the bilateral PFC may be related to depression symptomatology.

The mechanisms underlying the link between depression and MCI are currently unknown. One study revealed that depression may simply be an early manifestation of AD symptoms prior to cognitive decline [74]. A recent study demonstrated that there was increased Aβ accumulation in patients with an LMD, in comparison to patients without an LMD [20]. Our study focused selectively on aMCI patients, and our findings reinforce the previous literature, which reveals that an LMD may play a significant role in elevating the Aβ accumulation. There are findings suggesting that aMCI+LMD patients are at increased risk of

developing dementia than aMCI-LMD patients by more than two-folds [75]. Furthermore, a study revealed that patients with MCI who are PIB-positive are more likely to convert to AD patients than those who are PIB-negative [13]. All these findings suggest that both MCI patients with an LMD and MCI patients with high Aβ depositions are at a higher risk of developing AD. Thus, future longitudinal studies need to investigate the conversion rate from aMCI+LMD to AD in order to investigate whether LMD may be a strong predictor of AD.

There are limitations to the current investigation. First, the ADNI study did not specifically aim to explore the role of depression on Aβ accumulation, therefore the study did not include several details about depression, such as time since onset of depression, and the duration and number of depressive episodes (i.e., whether participants were continuously depressed, only depressed for a brief period, or if they had recurrent episodes). Another limitation of defining LMD involves underdiagnosis of depression during the time when the participants were diagnosed with depression [76], which may result in insufficient treatment of depression. As a result, these factors may influence the differences between the groups.

Second, the diagnosis of MD was based on clinical interviews with the participants; it was not obtained using a structured psychiatric interview. However, we addressed this issue by excluding participants with unspecified information about whether they met the Diagnostic and Statistical Manual of Mental Disorder criteria of MD. Third, there was a trend level difference in current GDS score between groups. To address this discrepancy, we included current depressive symptoms as a covariate in our analysis. Future studies should examine the relationship between current depressive symptoms and cortical Aβ accumulation using AV-45. Fourth, the study was limited by the use of the radiotracer AV-45 to quantify Aβ accumulation, as AV-45 may not bind to all Aβ plaques [77]. Fifth, the causality between Aβ and depression may be bi-directional. There are few studies showing that injection of Aβ oligomers and Aβ$_{1-42}$ peptide induce depressive-like behaviors in rats [78, 79]. Although these studies were carried out in rodents, findings from these studies suggest that high Aβ deposition may promote depression in humans. Sixth, many of the participants with an LMD were or had been on antidepressant medications for years. There has been one study showing that antidepressant may reduce CSF Aβ production in healthy individuals and transgenic AD mice [80]. However, future studies need to further investigate how

antidepressant usages affect cortical Aβ deposition in aMCI patients. Seventh, cortisol measures were not included as covariates in the analysis. Not every participant had cortisol measures, and among those who had them, there was a temporal discrepancy between cortisol assessments and PET scans. Given that cortisol may increase cortical Aβ formation [45], future studies need to investigate whether current cortisol level mediates the relationship between LMD and cortical Aβ deposition. Lastly, in addition to increased cortical Aβ deposition, other biomarkers of AD, such as hippocampal loss [81] and white matter hyperintensites [82], may be associated with LMD in aMCI population. A recent meta-analysis highlighted that late-life depression increases the risk of subsequent onset of both vascular dementia and AD, but the risk was higher for subsequent vascular dementia [83]. This finding suggests the importance of future studies investigating the relationship between LMD and different biomarkers for various types of dementia.

In conclusion, we found that the aMCI+LMD group had significantly higher AV-45 SUVR in the frontal region, in comparison to the aMCI-LMD group, controlling for current depressive symptoms, vascular risk factors, and the use of different PET scanners. Voxel-based analysis revealed that the difference was present mainly in the bilateral frontal regions. With two independent methods, we obtained consistent findings, which was higher frontal AV-45 SUVR in the aMCI+LMD group. We also observed in the voxel-based analysis a higher AV-45 SUVR in the right temporal region and left anterior cingulate, which was not observed in the ROI analysis. The voxel-based analysis may be a more sensitive method for small regions within larger ROIs. To sum up, our finding suggests that a region-specific frontal Aβ accumulation is associated with the occurrence of past depressive episodes in aMCI patients. Future prospective studies with larger sample sizes are necessary to replicate these findings and to further explore the mechanistic underpinnings of this relationship.

ACKNOWLEDGMENTS

the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2.

To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see http://www.adni-info.org

REFERENCES

[1] Jorm AF, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Kokmen E, Kondo K, Mortimer JA, Rocca WA, et al. (1991) Psychiatric history and related exposures as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. *Int J Epidemiol* **20**(Suppl 2), S43-S47.

[2] Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L (2003) Depression as a risk factor for Alzheimer disease: The MIRAGE Study. *Arch Neurol* **60**, 753-759.

[3] Speck CE, Kukull WA, Brenner DE, Bowen JD, McCormick WC, Teri L, Pfanschmidt ML, Thompson JD, Larson EB (1995) History of depression as a risk factor for Alzheimer's disease. *Epidemiology* **6**, 366-369.

[4] Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ (1991) Clinical risk factors for Alzheimer's disease: A population-based case-control study. *Neurology* **41**, 1393-1397.

[5] Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. *Arch Gen Psychiatry* **63**, 530-538.

[6] Jorm AF (2001) History of depression as a risk factor for dementia: An updated review. *Aust N Z J Psychiatry* **35**, 776-781.

[7] Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T (1993) The course of geriatric depression with "reversible dementia": A controlled study. *Am J Psychiatry* **150**, 1693-1699.

[8] Reynolds CF, 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ, Holm M, Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, Miller MD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, DeKosky ST (2011) Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. *Arch Gen Psychiatry* **68**, 51-60.

[9] Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* **10**, 819-828.

[10] Petersen RC (2000) Mild cognitive impairment: Transition between aging and Alzheimer's disease. *Neurologia* **15**, 93-101.

[11] Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA (2006) Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline. *Neurology* **67**, 441-445.

[12] Polyakova M, Sonnabend N, Sander C, Mergl R, Schroeter ML, Schroeder J, Schonknecht P (2014) Prevalence of minor depression in elderly persons with and without mild cognitive impairment: A systematic review. *J Affect Disord* **152-154** 28-38.

[13] Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. *Neurology* **73**, 754-760.

[14] Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. *JAMA* **288**, 1475-1483.

[15] Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Spalletta G (2010) Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: The role of depression and apathy. *J Alzheimers Dis* **20**, 175-183.

[16] Dotson VM, Beydoun MA, Zonderman AB (2010) Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. *Neurology* **75**, 27-34.

[17] Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V (2006) Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. *Arch Gen Psychiatry* **63**, 161-167.

[18] Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, Tsopelas ND, Lopresti BJ, Reynolds CF, 3rd, DeKosky ST, Meltzer CC (2008) Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. *Alzheimer Dis Assoc Disord* **22**, 261-268.

[19] Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry* **10**, 24-35.

[20] Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, Chang CJ, Tseng HJ, Yen TC, Liu CY, Lin KJ (2014) Increased brain amyloid deposition in patients with a lifetime history of major depression: Evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. *Eur J Nucl Med Mol Imaging* **41**, 714-722.

[21] Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, Burggren AC, Bookheimer SY, Huang SC, Barrio JR, Small GW (2009) Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. *Am J Geriatr Psychiatry* **17**, 493-502.

[22] Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW, Alzheimer's Disease NeuroImaging I (2011) Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. *Brain* **134**, 1077-1088.

[23] Alzheimer's Disease Neuroimaging Initative (2014) ADNI Website, http://adni.loni.usc.edu

[24] Alzheimer's Disease Neuroimaging Initiative (2010) ADNI General Procedures Manual, http://adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf

[25] Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.

[26] Wechsler D (1945) Wechsler memory scale.

[27] Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr* **9**(Suppl 1), 173-176; discussion 177-178.

[28] Alzheimer's Disease Neuroimaging Initiative (2008) ADNI 2 Procedures Manual, http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf

[29] Alzheimer's Disease Neuroimaging Initiative (2008) ADNI GO Procedures Manual, http://adni.loni.usc.edu/wp-content/uploads/2008/07/ADNI_GO_Procedures_Manual_06102011.pdf

[30] Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. *J Gerontol* **37**, 323-329.

[31] Yesavage JA (1988) Geriatric Depression Scale. *Psychopharmacol Bull* **24**, 709-711.

[32] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. *Neurology* **44**, 2308-2314.

[33] Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. *Ann Neurol* **7**, 486-488.

[34] Alzheimer's Disease Neuroimaging Initiative (2012) ADNI Procedure Manual-Alzheimer's Disease, http://www.adni-info.org/Scientists/Pdfs/adniproceduresmanual12.pdf

[35] Alzheimer's Disease Neuroimaging Initiative (2014) ADNI Study Documents, http://adni.loni.usc.edu/methods/documents/

[36] Alzheimer's Disease Neuroimaging Initiative (2014) ADNI_AV45_Methods_JagustLab_04.29.14.pdf, http://adni.bitbucket.org/ucberkeleyav45.html

[37] Alzheimer's Disease Neuroimaging Initiative (2011) ADNI 2 PET Technical Procedures Manual AV-45, http://adni.loni.usc.edu/wp-content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf

[38] Alzheimer's Disease Neuroimaging Initiative (2011) ADNI-GO PET Technical Procedures Manual AV-45 & FDG, http://adni.loni.usc.edu/wp-content/uploads/2010/05/ADNIGO_PET_Tech_Manual_01142011.pdf

[39] Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* **15**, 273-289.

[40] Madsen K, Hasselbalch BJ, Frederiksen KS, Haahr ME, Gade A, Law I, Price JC, Knudsen GM, Kessing LV, Hasselbalch SG (2012) Lack of association between prior depressive episodes and cerebral [11C]PiB binding. *Neurobiol Aging* **33**, 2334-2342.

[41] Alexopoulos GS (2003) Vascular disease, depression, and dementia. *J Am Geriatr Soc* **51**, 1178-1180.

[42] Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997) 'Vascular depression' hypothesis. *Arch Gen Psychiatry* **54**, 915-922.

[43] Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM (2007) Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. *Proc Natl Acad Sci U S A* **104**, 10673-10678.

[44] Byers AL, Yaffe K (2011) Depression and risk of developing dementia. *Nat Rev Neurol* **7**, 323-331.

[45] Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006) Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *J Neurosci* **26**, 9047-9056.

[46] Hurley LL, Tizabi Y (2013) Neuroinflammation, neurodegeneration, and depression. *Neurotox Res* **23**, 131-144.

[47] Reale M, Brenner T, Greig NH, Inestrosa N, Paleacu D (2010) Neuroinflammation, AD, and Dementia. *Int J Alzheimers Dis* **2010**, Article ID 974026, 2 pages, 2010. doi:10.4061/2010/974026

[48] Leonard BE (2007) Inflammation, depression and dementia: Are they connected? *Neurochem Res* **32**, 1749-1756.

[49] Bussiere T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, Giannakopoulos P, Robakis NK, Morrison JH, Perl DP, Hof PR (2002) Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. *Neuroscience* **112**, 75-91.

[50] Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. *Int Psychogeriatr* **9**(Suppl 1), 257-261; discussion 269-272.

[51] Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. *Arch Gen Psychiatry* **57**, 925-935.

[52] Bordji K, Becerril-Ortega J, Buisson A (2011) Synapses, NMDA receptor activity and neuronal Abeta production in Alzheimer's disease. *Rev Neurosci* **22**, 285-294.

[53] Piccinni A, Veltri A, Baroni S, Marazziti D, dell'Osso L (2014) Is there a role for β-amyloid in depression? *Clin Neuropsychiatry* **11**, 76-85.

[54] Galynker II, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D (1998) Hypofrontality and negative symptoms in major depressive disorder. *J Nucl Med* **39**, 608-612.

[55] Liao Y, Huang X, Wu Q, Yang C, Kuang W, Du M, Lui S, Yue Q, Chan RC, Kemp GJ, Gong Q (2013) Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. *J Psychiatry Neurosci* **38**, 49-56.

[56] Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, Rafi-Tari S (2004) Limbic-frontal circuitry in major depression: A path modeling metanalysis. *Neuroimage* **22**, 409-418.

[57] Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM (1989) Reduction of prefrontal cortex glucose metabolism common to three types of depression. *Arch Gen Psychiatry* **46**, 243-250.

[58] Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, Leroux JM, Bourgouin P, Beauregard M (2003) Neural circuitry underlying voluntary suppression of sadness. *Biol Psychiatry* **53**, 502-510.

[59] Koenigs M, Grafman J (2009) The functional neuroanatomy of depression: Distinct roles for ventromedial and dorsolateral prefrontal cortex. *Behav Brain Res* **201**, 239-243.

[60] Koenigs M, Huey ED, Calamia M, Raymont V, Tranel D, Grafman J (2008) Distinct regions of prefrontal cortex mediate resistance and vulnerability to depression. *J Neurosci* **28**, 12341-12348.

[61] Graff-Guerrero A, Gonzalez-Olvera J, Mendoza-Espinosa Y, Vaugier V, Garcia-Reyna JC (2004) Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naive patients. *J Affect Disord* **80**, 55-63.

[62] Hoffer ZS, Allen SL, Mathews M (2007) Treatment of psychiatric symptoms associated with a frontal lobe tumor through surgical resection. *Am J Psychiatry* **164**, 877-882.

[63] Cummings JL (1993) Frontal-subcortical circuits and human behavior. *Arch Neurol* **50**, 873-880.

[64] Shinagawa S (2013) Phenotypic variety in the presentation of frontotemporal lobar degeneration. *Int Rev Psychiatry* **25**, 138-144.

[65] Treadway MT, Waskom ML, Dillon DG, Holmes AJ, Park MT, Chakravarty MM, Dutra SJ, Polli FE, Iosifescu DV, Fava M, Gabrieli JD, Pizzagalli DA (2015) Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. *Biol Psychiatry* **77**, 285-294.

[66] Clark L, Manes F, Antoun N, Sahakian BJ, Robbins TW (2003) The contributions of lesion laterality and lesion volume to decision-making impairment following frontal lobe damage. *Neuropsychologia* **41**, 1474-1483.

[67] Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. *Trends Cogn Sci* **8**, 170-177.

[68] Grimm S, Beck J, Schuepbach D, Hell D, Boesiger P, Bermpohl F, Niehaus L, Boeker H, Northoff G (2008) Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: An fMRI study in severe major depressive disorder. *Biol Psychiatry* **63**, 369-376.

[69] Almeida OP, Burton EJ, Ferrier N, McKeith IG, O'Brien JT (2003) Depression with late onset is associated with right frontal lobe atrophy. *Psychol Med* **33**, 675-681.

[70] Marangell LB, Martinez M, Jurdi RA, Zboyan H (2007) Neurostimulation therapies in depression: A review of new modalities. *Acta Psychiatr Scand* **116**, 174-181.

[71] George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA (2010) Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. *Arch Gen Psychiatry* **67**, 507-516.

[72] Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012) Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. *Br J Psychiatry* **200**, 52-59.

[73] Bermpohl F, Fregni F, Boggio PS, Thut G, Northoff G, Otachi PT, Rigonatti SP, Marcolin MA, Pascual-Leone A (2006) Effect of low-frequency transcranial magnetic stimulation on an affective go/no-go task in patients with major depression: Role of stimulation site and depression severity. *Psychiatry Res* **141**, 1-13.

[74] Geerlings SW, Beekman AT, Deeg DJ, Van Tilburg W (2000) Physical health and the onset and persistence of depression in older adults: An eight-wave prospective community-based study. *Psychol Med* **30**, 369-380.

[75] Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Imbimbo BP, Santamato A, Vendemiale G, Seripa D, Pilotto A, Capurso A, Solfrizzi V (2010) Late-life depression, mild cognitive impairment, and dementia: Possible continuum? *Am J Geriatr Psychiatry* **18**, 98-116.

[76] Shorter E (2009) *Before Prozac: The Troubled History of Mood Disorders in Psychiatry*, Oxford University Press, New York.

[77] Levine H 3rd, Walker LC (2010) Molecular polymorphism of Abeta in Alzheimer's disease. *Neurobiol Aging* **31**, 542-548.

[78] Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, De Felice FG, Ferreira ST (2013) Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. *Mol Psychiatry* **18**, 1053-1054.

[79] Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, Cuomo V, Trabace L (2010) Soluble beta amyloid(1-42): A critical player in producing behavioural and biochemical changes evoking depressive-related state? *Br J Pharmacol* **159**, 1704-1715.

[80] Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, Cirrito JR (2014) An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. *Sci Transl Med* **6**, 236re234.

[81] Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, Alzheimer's Disease Neuroimaging I (2009) MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. *Brain* **132**, 1067-1077.

[82] Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME, Brickman AM, Alzheimer's Disease Neuroimaging I (2013) White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer disease? *JAMA Neurol* **70**, 455-461.

[83] Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd (2013) Late-life depression and risk of vascular dementia and Alzheimer's disease: Systematic review and meta-analysis of community-based cohort studies. *Br J Psychiatry* **202**, 329-335.